Skip to main content
. 2024 Apr 23;27(5):109800. doi: 10.1016/j.isci.2024.109800

Figure 3.

Figure 3

Lorlatinib inhibits the lung metastatic growth of HCC in mice

(A) Firefly luciferase-labeled SK-HEP-1 (SK-HEP-1-F-Luc) cells were injected into NSG mice (n = 8) to achieve lung metastasis, followed by treatment with lorlatinib (100 mg/kg) or vehicle (10% DMSO, 40% PEG 300, 5% Tween-80, and 45% saline) after 1 week of injecting the cells. Metastatic growth of SK-HEP-1-F-Luc cells was monitored using F-Luc-based bioluminescence imaging. Mouse bioluminescence images at the indicated time points are shown.

(B) Bioluminescent intensities (arbitrary units) for the mice shown in (A) are plotted. For p = 0.2433 (week 1, vehicle versus lorlatinib (n = 8 each)), t = 1.218, df = 14, and p = 0.0008 (week 3, vehicle (n = 8) versus lorlatinib (n = 7)), t = 4.356, df = 13. p values were calculated using a two-tailed, unpaired Student’s t test.

(C) Bioluminescence images of the lungs of mice isolated at the end of the experiment from the mice shown in (A). Data are presented as the mean ± SEM.